Intellectual Property - April 24, 2020
Spago Nanomedical’s Tumorad patent approved in Japan
Spago Nanomedical has received notice of allowance for the company’s patent application including Tumorad product protection in Japan. ”The patent covers the nanomaterial that is central for the Tumorad-project. As Japan represent a potentially large market for radionuclide therapies, this approval is important. It also underscores the quality of our innovation and strengthens the commercial […]
Intellectual Property - March 12, 2020
Cantargia acquires Cellerant IP on IL1RAP
Cantargia has announced the acquisition of a patent portfolio from Cellerant Therapeutics Inc covering aspects around the interleukin 1 receptor accessory protein (IL1RAP). The acquired IP includes a US patent on IL1RAP as a target for antibody therapy in leukemia. Thereby, Cantargia has broadened its IP portfolio and secured ownership of the key patents around […]
Intellectual Property - February 26, 2020
Xbrane files three patent applications
Xbrane Biopharma has filed three patent applications covering novel nucleic acid sequences encoding various signal peptides that have been demonstrated to have significant impact on yield and thereby production cost of recombinant proteins. “We are an innovative company continuously strengthening our platform technology with the focus of having the lowest production cost in the industry […]
Intellectual Property - February 18, 2020
Photocure announces new US patent for Hexvix
Photocure has announced that the United States Patent and Trademark Office (USPTO) has granted US Patent covering the use of Blue Light Cystoscopy (BLC) with Hexvix as neoadjuvant therapy in the treatment of bladder cancer in patients who are scheduled for a cystectomy. Early stage study results have shown an anti-tumor effect and induced systemic […]
Intellectual Property - February 17, 2020
AroCell patent approved in China
AroCell has announced that the patent titled “Monoclonal anti-TK1 antibodies” is granted by China National Intellectual Property Administration (CNIPA). The patent relates to AroCell’s monoclonal antibodies used for determining the Thymidine kinase 1 concentration in serum samples. The antibodies approved in the patent is used in the AroCell TK 210 ELISA kit. “We are delighted […]
Intellectual Property - February 10, 2020
AroCell patent granted in the US
AroCell has announced that the patent regarding the method of determining a likelihood of cancer relapse is now granted by United States Patent and Trademark Office. The patent claims the method of determining a likelihood of cancer relapse in a subject who has completed cancer tumour surgery, radiotherapy treatment and/or chemotherapy treatment comprises contacting an […]
